[2].Ruggeri M, Pagan E, Bagnardi V, et al, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers. Breast. 2019 Oct;47:85-92....
Her2-positive breast cancer in a young patient with Li-Fraumeni syndrome: A comprehensive case studyIntroduction and importance Li-Fraumeni syndrome (LFS) is a rare hereditary disorder caused by mutations in the TP53 gene, leading to a significantly increased risk of developing various cancers at a...
12 The study assessed the combination in patients with hormone receptor–positive, HER2-negative breast cancer and residual invasive disease after neoadjuvant chemotherapy. Although the PALLA and PENELOPE-B findings were anticlimactic compared with the practice-changing data observed in the me...
Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J. Clin....
publication of the BOLERO-1 study4, spoke on this phase III, double-blind, randomized, multicenter trial that evaluated the efficacy and safety of adding the mTOR inhibitor everolimus to trastuzumab and paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer. The...
a her2-let-7-β2-ar circuit affects prognosis in patients with her2-positive breast cancer:一个her2-let-7 -β2-ar电路影响预后的her2阳性乳腺癌患者 热度: HER2阳性乳腺癌治疗原则 热度: HER2-PositiveBreastCancer CompetitiveMonitoring& StrategicAnalysis ...
The blood–tumour barrier in cancer biology and therapy. Nat. Rev. Clin. Oncol. 18, 696–714 (2022). Article Google Scholar Lin, N. U. et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15, 1452–1459...
Safety of trastuzumab emtansine (T-DM1) in 373 patients 65 years or older with HER2-positive advanced breast cancer: A subgroup analysis of the Kamilla study CH Barrios,A Anton,S Delaloge,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2015年 Trastuzumab emtansine versus treatment of...
The Perjeta-based regimen continued to reduce the risk of breast cancer recurrence or death versus Herceptin, chemotherapy and placebo, by 23% in the overall study population (iDFS, HR=0.77, 95% CI 0.66-0.91). More people who received post-surgery treatment with the Perjeta-based regimen remai...
Prediction of late distant recurrence in patients with oestrogen-receptor–positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;14(11):1067-1076.PubMedGoogle ScholarCross...